---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Natural history, survival, and mortality"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Natural history, survival, and mortality. Topics: Lifelong course with associated morbidity; No cure: management aims; Age at onset: bimodal distribution; Age at diagnosis, 1970 to 1999; 7 further topics. 11 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Lifelong course with associated morbidity

> “Psoriasis is a lifelong immune-mediated inflammatory skin disease, associated with morbidities such as psoriatic arthropathy, psychological, cardiovascular and hepatic diseases.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.3-2"></a>

### No cure: management aims

> “Psoriasis cannot currently be cured, but management should aim to minimise physical and psychological harm by treating patients early in the disease process, identifying and preventing associated multimorbidity, instilling lifestyle modifications, and employing a personalised approach to treatment.”

Source: [Griffiths et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33812489/)

<a id="topic-2.2.1.3-3"></a>

### Age at onset: bimodal distribution

> “Findings revealed consistency across studies about the bimodal age pattern of the onset of the disease.”
> “When we examined the incidence of psoriasis by sex and age bands, the two peaks for age at onset in women were more frequently around 18-29 and 50-59 years, whereas in men they occurred more frequently around 30-39 and 60-69 or 70-79 years.”

Source: [Parisi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7254147/)

<a id="topic-2.2.1.3-4"></a>

### Age at diagnosis, 1970 to 1999

> “The mean age at diagnosis (± standard deviation) of psoriasis was 43.2 ± 17.0 years and 828 (51.0%) subjects were male (Table 1).”
> “Average age at incidence increased across the three decades from 39.8 years in 1970–1979, to 41.9 years in 1980–1989 and 45.5 years in 1990–1999 (p<0.001).”

Source: [Icen et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3028518/)

<a id="topic-2.2.1.3-5"></a>

### Progression between clinical forms and erythroderma

> “Patients with guttate psoriasis may later develop plaque psoriasis. In rare cases of severe uncontrolled disease, psoriasis causes a widespread erythematous rash (erythroderma) that is life-threatening due to potential complications including hypothermia, risk of infection, acute kidney injury and high-output cardiac failure.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.3-6"></a>

### Mortality and life expectancy in severe psoriasis

> “There was no overall effect of mild psoriasis on mortality (HR, 1.0; 95% confidence interval [CI], 0.97-1.02), whereas patients with severe psoriasis demonstrated an increased overall mortality risk (HR, 1.5; 95% CI, 1.3-1.7).”
> “Male and female patients with severe psoriasis died 3.5 (95% CI, 1.2-5.8) and 4.4 (95% CI, 2.2-6.6) years younger, respectively, than patients without psoriasis (P < .001).”

Source: [Gelfand et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/18086997/)

<a id="topic-2.2.1.3-7"></a>

### Cause-specific mortality and age at death in severe psoriasis

> “Patients with severe psoriasis were at increased risk of death from cardiovascular disease (HR 1.57; 95%CI 1.26–1.96), malignancies (HR 1.41; 95%CI 1.07–1.86), chronic lower respiratory disease (HR 2.08; 95%CI 1.24–3.48), diabetes (HR 2.86; 95%CI 1.08–7.59), dementia (HR 3.64; 95%CI 1.36–9.72), infection (HR 1.65; 95%CI 1.26–2.18), kidney disease (HR 4.37; 95%CI 2.24–8.53), and unknown/missing causes (HR 1.44; 95%CI 1.09–1.88).”
> “Overall, psoriasis patients died at a younger age than unexposed patients (mean age of 73 vs 79 years respectively, p<0.001), as shown graphically in Figure 1.”

Source: [Abuabara et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2966545/)

<a id="topic-2.2.1.3-8"></a>

### Cardiovascular mortality in severe psoriasis

> “Severe psoriasis was an independent risk factor for CV mortality (HR 1.57; 95% CI 1.26, 1.96) when adjusting for age, sex, smoking, diabetes, hypertension, and hyperlipidaemia. Overall, severe psoriasis patients experienced one extra CV death per 283 patients per year, even when adjusting for major CV risk factors.”
> “For example, the RR of CV death for a 40-year-old and 60-year-old with severe psoriasis was 2.69 (1.45, 4.99) and 1.92 (1.41, 2.62), respectively.”

Source: [Mehta et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2894736/)

<a id="topic-2.2.1.3-9"></a>

### All-cause and cardiovascular mortality by severity: meta-analysis of 12 studies

> “We included 12 studies. The pooled RRs for all-cause mortality were 1.21 (95% CI 1.14-1.28) in psoriasis, 1.13 (95% CI 1.09-1.16) in mild psoriasis, and 1.52 (95% CI 1.35-1.71) in severe psoriasis. The pooled RRs for cardiovascular mortality were 1.15 (95% CI 1.09-1.21) in psoriasis, 1.05 (95% CI 0.92-1.20) in mild psoriasis, and 1.38 (95% CI 1.09-1.74) in severe psoriasis.”
> “For noncardiovascular causes, mortality risk from liver disease, kidney disease, and infection was significantly increased in psoriasis, regardless of disease severity.”

Source: [Dhana et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30590074/)

<a id="topic-2.2.1.3-10"></a>

### All-cause mortality over a median follow-up of 52.3 months

> “Over an average median follow-up of 52.3 months, psoriasis was significantly associated with increased mortality risk (HR, 1.99; 95% CI, 1.01-3.93; P = .047) with adjustment for demographics, smoking, and comorbidities including cardiovascular disease, diabetes, chronic obstructive pulmonary disease, cancer, chronic kidney disease, and stroke.”

Source: [Semenov et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/31415837/)

<a id="topic-2.2.1.3-11"></a>

### Survival compared with the Minnesota white population

> “Survival in the overall psoriasis cohort was similar to that expected in the Minnesota white population (standardized mortality ratio [SMR]: 0.95, 95% CI: 0.84, 1.07, p=0.36) over the entire time period.”

Source: [Icen et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3028518/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
